Alpha DaRT Advanced Pancreatic Cancer Trial: Alpha Tau Announces Highly Promising Interim Results; CEO to Present Company Overview on Thursday, January 11, at JP Morgan Healthcare Conference; Live Webcast Available

On Novemer 28, 2023, Alpha Tau Medical Ltd. ("Alpha Tau,” or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced the release of interim results from treatment of the first five patients in the Company’s safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer, currently underway at two university hospitals in Montreal, Canada. The first five patients were treated at the Jewish General Hospital, an affiliated teaching hospital of McGill University, Faculty of Medicine, in Montreal, Canada, in accordance with the study protocol calling for a pace of approximately one patient per month, pending results from the interim safety read-out from the first five patients. Levels of radium-224 activity were increased from one patient to the next. Tumor stages of the treated patients ranged from stage II to stage IV, and treated tumors were located in the pancreatic head or neck. Four of the five patients had been previously treated with chemotherapy before enrolling in the study.

Login Or Register To Read Full Story